References
- Wingard JR, Kubilis P, Lee I, Yee G, White M, Walshe L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29: 1402–7
- Johnson LB, Kauffman C. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630–7
- Sable C, Nguyen B-Y T, Chodakewitz JA, DiNubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002; 4: 25–30.
- Andriole VT. Current and future antifungal therapy: new targets for antifungal agents. J Antimicrob Chemother 1999; 44: 151–62.
- Martinez-Suarez JV, Rodriguez-Tudela JL. In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates. Antimicrob Agents Chemother 1996; 40: 1277–9